BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17335931)

  • 1. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.
    Abraldes JG; Rodríguez-Vilarrupla A; Graupera M; Zafra C; García-Calderó H; García-Pagán JC; Bosch J
    J Hepatol; 2007 Jun; 46(6):1040-6. PubMed ID: 17335931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis.
    Gracia-Sancho J; Laviña B; Rodríguez-Vilarrupla A; Brandes RP; Fernández M; Bosch J; García-Pagán JC
    Gastroenterology; 2007 Sep; 133(3):959-66. PubMed ID: 17854599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
    Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
    J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
    Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
    Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.
    Zhang ZQ; Qiu JF; Luo M; Sun YW; Zhao G; Chen W; Liu H; Wu ZY
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e487-93. PubMed ID: 18070013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers.
    Cho YK; Yun JW; Park JH; Kim HJ; Park DI; Sohn CI; Jeon WK; Kim BI; Jin W; Kwon YH; Shin MK; Yoo TM; Kang JH; Park CS
    Life Sci; 2009 Aug; 85(7-8):281-90. PubMed ID: 19527736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats.
    Huang HC; Wang SS; Lee JY; Chen YC; Lee FY; Lin HC; Chang CC; Lee SD
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1401-9. PubMed ID: 20659230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis.
    Matei V; Rodríguez-Vilarrupla A; Deulofeu R; Colomer D; Fernández M; Bosch J; Garcia-Pagán JC
    Hepatology; 2006 Jul; 44(1):44-52. PubMed ID: 16799985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats.
    Malyshev E; Tazi KA; Moreau R; Lebrec D
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2195-201. PubMed ID: 18031380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.
    Loureiro-Silva MR; Iwakiri Y; Abraldes JG; Haq O; Groszmann RJ
    J Hepatol; 2006 May; 44(5):886-93. PubMed ID: 16545481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats.
    Gupta TK; Toruner M; Chung MK; Groszmann RJ
    Hepatology; 1998 Oct; 28(4):926-31. PubMed ID: 9755227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
    Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
    Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NO as an indicator of portal hemodynamics and the role of iNOS in increased NO production in CCl4-induced liver cirrhosis.
    Mizumoto M; Arii S; Furutani M; Nakamura T; Ishigami S; Monden K; Ishiguro S; Fujita S; Imamura M
    J Surg Res; 1997 Jul; 70(2):124-33. PubMed ID: 9245560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dexamethasone, an inhibitor of the expression of inducible nitric oxide synthase, does not modify the hyperdynamic state in cirrhotic rats].
    Albornoz L; Bandi JC; de las Heras M; Mastai R
    Medicina (B Aires); 2000; 60(4):477-81. PubMed ID: 11188955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
    Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.